Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
December 17, 2018 06:00 ET
|
Athersys, Inc.
CLEVELAND, Ohio, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow...
Athersys Reports Third Quarter 2018 Results
November 06, 2018 16:05 ET
|
Athersys, Inc.
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended...
Athersys to Host Third Quarter Financial Results Call
October 09, 2018 16:00 ET
|
Athersys, Inc.
CLEVELAND, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November...
Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
September 24, 2018 06:00 ET
|
Athersys, Inc.
CEO invited to provide corporate overview and speak in two workshops focusing on innovative development initiatives in Japan and advanced manufacturing technologies CLEVELAND, Ohio, Sept. 24, 2018 ...
Athersys Reports Second Quarter 2018 Results
August 07, 2018 16:05 ET
|
Athersys, Inc.
CLEVELAND, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2018. Highlights of the second quarter of 2018...
Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
August 03, 2018 06:00 ET
|
Athersys, Inc.
CLEVELAND, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and...
Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
July 31, 2018 06:00 ET
|
Athersys, Inc.
Pivotal study has received a Special Protocol Assessment (SPA), Fast Track Designation, and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) ...
Athersys to Host Second Quarter Financial Results Call
July 10, 2018 16:00 ET
|
Athersys, Inc.
CLEVELAND, July 10, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7th, 2018,...
Athersys Announces Expansion of Collaboration With Healios
June 07, 2018 06:00 ET
|
Athersys, Inc.
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties Discussions extended...
Athersys Announces Expansion of Collaboration With Healios
June 07, 2018 02:00 ET
|
Athersys, Inc.
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties Discussions extended...